Top Biotech Companies With Best Stability & Growth (3,227)
Biotechnology is rewriting life as we know it, from the medicines we take, to the crops we grow, and the household goods that we rely on every day. But moving at the new speed of science requires better technology. Benchling’s mission is to unlock the power of biotechnology. The world’s most innovative biotech companies use Benchling’s R&D Cloud to power the...
Benchling's Top Stability & Growth Strengths
Strong Revenue Growth: ARR was estimated around $200M+ by mid-2024 with year-over-year increases, alongside a larger customer base and higher revenue per customer. These signals indicate ongoing expansion in core subscription economics.
Strategic Partnerships: An expanded collaboration with Moderna bringing hundreds of scientists onto a unified, AI-ready environment signals deepening penetration in large biopharma accounts. Such marquee expansions reinforce credibility and create room for further account growth.
Product Line Growth: The company has shipped frequent platform updates, launched AI capabilities, and integrated partners like NVIDIA NIM, while adding offerings such as Benchling Bioprocess and via the PipeBio acquisition. This broadens the product surface area and supports land-and-expand motions.
SOPHiA GENETICS (Nasdaq: SOPH) is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform...
SOPHiA GENETICS's Top Stability & Growth Strengths
Strong Revenue Growth: Revenue continues to rise at a double‑digit pace year over year with acceleration into year‑end. Management reaffirmed guidance for another year of meaningful top‑line expansion.
Market Expansion: The customer base and analysis volumes increased to record levels, and two large U.S. integrated health systems are expected to add substantial annual throughput as implementations ramp in the second half of 2026. Net dollar retention improved, indicating deeper adoption within existing institutions.
Strategic Partnerships: Collaborations with leading cancer centers and biopharma (e.g., MSK‑ACCESS powered with SOPHiA DDM, AstraZeneca, MD Anderson) are expanding product adoption and opening key U.S. channels. These alliances signal validation of the platform and support growth in high‑value applications like liquid biopsy.
Click Therapeutics, Inc., develops, validates, and commercializes software as prescription medical treatments for people with unmet medical needs. As a leading innovator of Digital Therapeutics™, Click delivers accessible, clinically proven, FDA-regulated prescription treatments to the smartphone in your hand. Click’s treatments are defined by a commitment to applying technical and scientific rigor and patient-centric design to the development process. This...
Click Therapeutics's Top Stability & Growth Strengths
Investor Backing & Capital Strength: Fresh capital includes a $50M Series D on April 9, 2026 led by Boehringer Ingelheim and a 2025 Series C with Dassault Systèmes/Medidata to fund commercialization and platform scaling. Feedback suggests these transactions reflect strong external confidence and provide runway to advance regulatory and launch efforts.
Product Line Growth: Multiple FDA authorizations (Rejoyn in 2024; CT‑132 in 2025), positive Phase 3 data for CT‑155, and acquisition of Better Therapeutics’ assets expand the portfolio across psychiatry, neurology, and cardiometabolic conditions. A 2026 Ultrahuman partnership further extends migraine technology into adjacent offerings.
Strategic Partnerships: Multi‑year collaborations with Boehringer Ingelheim and Otsuka, plus ecosystem ties with Dassault Systèmes/Medidata and Ultrahuman, underpin development and prospective commercialization. These alliances distribute risk and provide capabilities and channels that many peers lack.
.png)
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is using the power of high-intensity sequencing, population-scale clinical studies, and state-of-the-art computer science and data science to enhance the scientific understanding of cancer biology, and to develop and commercialize pioneering products.
GRAIL's Top Stability & Growth Strengths
Strong Revenue Growth: Revenue and test volumes are rising, with 2025 total revenue up year over year to $147.2M, U.S. Galleri revenue up, and more than 185,000 tests sold; quarterly updates also showed double‑digit growth.
Strategic Partnerships: Access expanded through TRICARE coverage, Quest Diagnostics ordering integration, digital‑health channels, and health‑system/EHR integrations, alongside international collaborations such as Samsung and a Canada launch.
Investor Backing & Capital Strength: Funding raised in 2025 and a reported cash balance exceeding $850M provide runway into 2030, supporting continued commercialization and regulatory efforts.
Formation Bio is a tech-driven pharma company differentiated by radically more efficient drug development. Formation Bio has built a technology platform that optimizes all aspects of drug development, enabling more efficient trial design, faster trial completion, and higher quality trial data capture. Formation Bio acquires clinical-stage drugs from pharma and biotech and develops them faster and more efficiently, unlocking greater...
Formation Bio's Top Stability & Growth Strengths
Investor Backing & Capital Strength: Raised a $372 million Series D on June 26, 2024 with strategic participation from Sanofi, bringing total financing to roughly $600M+. This level of capital is described as supporting headcount expansion, pipeline acquisitions, and platform build‑out.
Strategic Partnerships: Entered a first‑of‑its‑kind AI collaboration with Sanofi and OpenAI in May 2024, later highlighted by Sanofi in its filings. Additional Sanofi-linked licensing activity signals commercial traction and scale ambitions.
Product Line Growth: Created Bleecker Bio and signed a December 2025 deal to develop Lynk Pharma’s TYK2 inhibitor (milestones up to $605M) with a Phase 1 start targeted for H1 2026. Disclosed programs, including at least one in Phase 3, indicate an expanding internal portfolio.
Schrödinger is a leading provider of advanced molecular simulations and enterprise software solutions and services for pharmaceutical, biotechnology, and materials science research. The predictive power of Schrödinger's software allows scientists to accelerate their research and development, reduce research costs, and make novel discoveries.
Schrödinger, Inc.'s Top Stability & Growth Strengths
Strong Revenue Growth: 2025 results show total revenue increased meaningfully year over year, with software higher and drug‑discovery contributions expanding. Management also guides continued expansion into 2026 as measured by software ACV.
Strategic Partnerships: Large, multi‑target collaborations (e.g., with Novartis) and integrations with leading pharmas (e.g., Lilly) reinforce commercial traction and ecosystem reach. These relationships support both recurring software usage and potential milestone‑driven upside.
Future-Ready Strategy: Accelerating the shift from on‑premise to hosted licensing is intended to make revenue more predictable and better align recognition with contract value. 2026 priorities emphasize platform scaling, new offerings like predictive toxicology, and deeper partner integrations.
Our purpose ensures that patients remain at the center of all we do. We live our purpose by sourcing the best science in the world; partnering with others in the healthcare system to improve access to our medicines; using digital technologies to enhance our drug discovery and development, as well as patient outcomes; and leading the conversation to advocate for...
Pfizer's Top Stability & Growth Strengths
Diversified Revenue Streams: Non‑COVID portfolio momentum across oncology, vaccines, and cardiovascular is contributing, with Eliquis, Prevnar, Vyndaqel, and Seagen‑derived assets cited as growth drivers. This breadth helps offset the normalization of COVID products.
Cost & Operational Efficiency: Adjusted diluted EPS rose in 2025 versus 2024, attributed to cost realignment and mix. Ongoing cost‑saving and manufacturing optimization programs are intended to support margins through mid‑decade.
Future-Ready Strategy: Management highlights oncology and next‑generation assets, with Seagen’s ADC platform and pending data/approvals expected to support medium‑term growth. Pipeline catalysts into 2026 position the company for potential re‑acceleration if execution lands as planned.
Flatiron Health is a healthtech company dedicated to helping cancer centers thrive and deliver better care for patients today and tomorrow. Through clinical and data science, we translate patient experiences into real-world evidence to improve treatment, inform policy, and advance research. Cancer is smart. Together, we can be smarter. Flatiron Health is an independent affiliate of the Roche Group.
Flatiron Health's Top Stability & Growth Strengths
Product Line Growth: Flatiron rolled out AI-powered Panoramic datasets across major tumor types and launched new hematology datasets built from 505k+ blood cancer records, expanding the breadth and depth of its offerings. Ongoing research acceptances and a peer-reviewed validation framework for AI-extracted oncology data indicate continued product maturation.
Market Expansion: The company reported tripling its global research network to 30+ institutions across Europe and Japan by mid‑2025 and highlighted multinational dataset launches, signaling a broader international footprint. Establishing a Raleigh‑Durham Life Sciences Hub further reflects geographic growth.
Strategic Partnerships: Collaborations to accelerate trial enrollment and enhance clinico‑genomic offerings (e.g., Massive Bio, Caris) and a renewed multi‑year collaboration with FDA support sustained external momentum. A long‑term partnership with Paradigm following the 2025 divestiture reinforces a partner‑led services approach around its core platform.
At Inato, we’re on a mission to accelerate the pace of medical innovation by bringing clinical research to each and every patient, regardless of who they are and where they live. Our platform, made to connect community-based research centers to trials across the globe, aims to create greater visibility, access, and engagement across a more diverse population of doctors and...
Inato's Top Stability & Growth Strengths
Market Expansion: Public materials indicate the network scaled from over 2,500 community sites in 2023 to 6,000+ research sites and 25+ sponsors across 50+ countries by April 2026. This sequential ramp across sites, sponsors, and geographies suggests continued expansion on both sides of the marketplace.
Strategic Partnerships: New and expanding collaborations—such as AbbVie oncology rollouts and integrations with RealTime eClinical Solutions and CRIO—point to growing demand-side traction and data connectivity. These relationships embed the platform into sponsor and site workflows, reinforcing usage and reach.
Innovation-Driven Growth: The company launched AI Site Selection and AI-powered patient pre-screening in 2025, with 2026 case posts highlighting time and cost savings on active studies. This product velocity and real-world application signal ongoing innovation tied to operational outcomes.
We bring together one of the world’s largest libraries of multimodal clinical and molecular data with a robust suite of AI tools to help physicians personalize care in real time, connect patients with therapies and clinical trials, and enable partners to accelerate discovery and development of new treatments. With ~8 million de-identified research records and 350+ petabytes of data, Tempus partners...
Tempus AI's Top Stability & Growth Strengths
Strong Revenue Growth: Reported total net revenue rose from $693.4 million in 2024 to about $1.27 billion in 2025, with Q4 2025 also showing strong year‑over‑year growth. Management guides 2026 revenue to roughly $1.59 billion, indicating continued expansion.
Customer Loyalty & Retention: Disclosed net revenue retention of approximately 126% and total remaining contract value exceeding $1.1 billion signal expanding multi‑year demand. These metrics indicate existing customers are increasing spend and extending commitments.
Strategic Partnerships: Multi‑year collaborations with major pharmas and health systems—including a three‑year, $200 million data/modeling agreement with AstraZeneca/Pathos and an expanded Merck collaboration—support growth in data licensing and AI applications. Partnerships with top‑tier sponsors evidence strong demand for the platform.
Flourish Research is a fully integrated clinical trial organization in North America. We acquire and operate large, best-in-class sites with the very best medical and scientific expertise, meaningful diversity, and reliable recruitment. The Flourish Difference: Meaningful Diversity - We constantly innovate our approach to support diversity in our patient populations and employees. Exceptional Scale and Agility - By acquiring and operating some of...
We are building a synthetic alternative to cell therapies—a tunable, cell-free system that mimics regenerative signaling with precision across indications. Our first candidate targets Osteoarthritis.
Deductive AI is an applied AI research lab building AGI to enable self-healing software systems. Our code-aware observability platform helps numerous companies root-cause and mitigate large-scale software outages by reasoning about distributed systems, code, and statistical anomalies in real time across unprecedented volumes of structured and unstructured data. We’re a team of engineers and researchers with decades of experience building and...
FMC Corporation is an US-based chemical manufacturing company producing solutions for the agricultural, textile, and healthcare industries. FMC Corporation is a global agricultural sciences company dedicated to helping growers produce food, feed, fiber and fuel for an expanding world population while adapting to a changing environment. FMC’s innovative crop protection solutions – including biologicals, crop nutrition, digital and precision agriculture –...
Tackling a global health threat like antimicrobial resistance is not for the faint of heart, but the experienced and innovative team at Pattern Bioscience is on a mission to do it. Each year, drug-resistant bacterial infections claim more than a million lives globally and cost our healthcare system billions of dollars. Traditional diagnostic methods for bacterial infections remain rooted in...
ArsenalBio is a privately held, programmable cell therapy company focused on the realization of solid tumor cell therapy to defeat cancer. Our discovery engine comprises precise CRISPR-enabled genome editing, integrated circuits incorporating logic gates for improved tumor targeting, and therapeutic enhancements enabling multiple pharmaceutical functions. With our programmable and computationally driven approach, we aim for enhanced and broader efficacy, increased...
Caron Products & Services, Inc. is a leading manufacturer of laboratory equipment for environmental testing, incubation, and controlled environments, serving industries such as biopharmaceutical, biotechnology, and academic research.
Emerald Cloud Lab is a remote controlled life science laboratory that allows scientists to conduct their experiments without being anchored to a physical lab. In our cloud lab, experiments are driven by issuing commands over the internet, which are then run in a vast, highly automated central facility which operates 24 hours a day, 7 days a week, 365 days...
We Engineer Solutions for the Nation’s Toughest Problems As an independent nonprofit engineering innovation company, Draper provides engineering services directly to government, industry, and academia. We work on teams as prime contractors or subcontractors and participate as collaborators in consortia. Our strong commitment to delivering working solutions allows us to apply ourselves to a variety of domains from space to undersea —...
Lucis focuses on Function Health for Europe, aiming to address preventable chronic diseases.
